Biomarker discovery using Protein Arrays
Characterisation of protein binder specificity and cross-reactivity
- Poly-, monoclonal antibodies, phage binders
- Cancer biomarker antibodies
Profiling of antibody repertoire in sera, CSF, and other fluids.
- Colorectal cancer
- Breast cancer
- Glaucoma
Identification of protein-protein/peptide interactions
- Delineation of biological pathways (Bcl-2 family proteins, NF-kappaB signalling)
Reverse Phase Protein Arrays (RPPA)
RPPA are a high-throughput antibody-based technique developed for Functional Proteomics studies to evaluate protein activities in signaling networks.
At present, more then 400 antibodies have been validated for the use in the RPPA Platform. These antibodies cover all the major protein pathways in the cell:
- Angiogenesis
- Apoptosis
- Autophagy
- Cancer drug targets
- Cell cycle regulation
- Cellular senescence
- DNA damage signaling
- DNA repair
- JAK/STAT signaling
- MAP Kinasesignaling
- Necrosis
- NFkB signaling
- P53 signaling
- PI3K-AKT signaling
- Signal transduction
- Stress and Toxicity
RPPA can be applied to fresh and FFPE tissue samples alike:
